Allometric scaling for prediction of clinical PK parameters from preclinical data.
Modelling of the mammalian cell cycle and cell cycle checkpoints, signal transduction and apoptosis.
Use of differential pharmacodynamics to predict in vivo activity from in vitro data and optimise the design of in vivo combination studies.
Analysis of drug combination data and quantitation of synergism and antagonism by the method of Greco.
Pharmacokinetic/pharmacodynamic modelling of biomarker data.
Nonlinear regression analysis of enzyme inhibition data by the tight-binding inhibition equation of Morrison.